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European 
Perspective of 
2-Person Rule for 
Biosafety Level 4 
Laboratories
To the Editor: Recently, the di-
rectors of Biosafety Level 4 (BSL-4) 
laboratories in the United States pub-
lished their views of the requirement 
of having ≥2 persons present at all 
times while biological work is under-
taken in a BSL-4 laboratory (1). They 
concluded that safety and security 
would be better assured in some situ-
ations by video monitoring systems 
rather than by the presence of a fellow 
scientist. As members of the European 
Network of Biosafety Level-4 labo-
ratories (Euronet-P4) who have de-
veloped guidelines in this area (2–4), 
we discussed the article during a re-
cent network meeting. Biosafety and 
biosecurity are the major concerns 
for all involved in BSL-4 activities, 
and we support the authors’ initiative 
and broadly agree with their posi-
tion. The consensus among European 
BSL-4 experts is that, in the interest of 
safety, standard practice should be for 
all laboratories to perform a risk as-
sessment before any activity is under-
taken. This preliminary assessment is 
the best way to determine procedures 
to be used, including whether 2 per-
sons should work together as part of 
laboratory procedure. A 2-person rule 
is inappropriate simply because the 
best approach is not to have inﬂ  exible 
rules that are not objectively assessed 
according to laboratory-speciﬁ  c  cir-
cumstances.
Surveillance video monitoring 
and data storing have their place in 
protecting laboratory facilities from 
unauthorized access and theft of ma-
terials, but their effectiveness for en-
suring proper handling of pathogens 
is quite limited. Finally, we agree with 
the authors that both biosafety and 
biosecurity must be founded on care-
ful selection and monitoring of staff, 
without which even the most sophisti-
cated of control systems would fail.
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Multidrug-Resistant 
Mycobacterium 
tuberculosis Strain 
from Equatorial 
Guinea Detected 
in Spain
To the Editor: Eleven years of 
molecular epidemiologic data allowed 
the Spanish Multidrug-resistant Tu-
berculosis (MDR TB) Surveillance 
Network to identify a speciﬁ  c MDR 
Mycobacterium tuberculosis strain 
that had been imported into Spain 
from Equatorial Guinea (1). Our study 
brings to light the potential dissemi-
nation of this strain (named MDR-
TBEG) in Equatorial Guinea, a coun-
try where little is known about the 
extent and features of TB or MDR TB. 
It also highlights that MDR strains 
can spread across continents, and thus 
MDR TB’s emergence in any country 
becomes a global problem.
Ten MDR M. tuberculosis isolates 
obtained from 10 patients from Equa-
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torial Guinea were detected in Spain 
during 2000 through 2008. Evidence 
of clonality was found within the 10 
isolates because all exhibited identi-
cal genetic proﬁ  les deﬁ  ned by differ-
ent molecular epidemiology methods 
(2,3) and mutations involved in drug 
resistance (Figure). Notably, none of 
the remaining 504 MDR isolates in the 
Spanish database matched SIT177, a 
spoligotype belonging to the Latin 
American–Mediterranean 9 (LAM9) 
subfamily (4).
The data routinely collected for all 
cases of MDR TB have been previous-
ly described (1). All 10 patients in the 
study were from Equatorial Guinea, a 
small African country on the Gulf of 
Guinea with a population of ≈500,000, 
an MDR TB rate >2.0% (5) of all com-
bined (new and previously treated) 
TB cases, and an estimated adult HIV 
prevalence rate of 3.2% (www.who.
int/globalatlas/predefinedReports/
EFS2008/full/EFS2008_GQ.pdf). 
The MDR TB isolates were collected 
within a 9-year period (online Techni-
cal Appendix, available from www.
cdc.gov/EID/content/15/11/1858-
Techapp.pdf): 1 in 2000, 2 in 2001, 
3 in 2003, 1 in 2004, 2 in 2007, and 
1 in 2008. According to their hospi-
tals of origin, the patients were geo-
graphically dispersed in 6 different 
Spanish cities. We found that the in-
terval between the patients’ arrival in 
Spain to the initiation of anti-TB treat-
ment was <3 months in 6 patients, 3 
of whom were clinically ill at the time 
of arrival. Seven patients were adult 
men, 2 were adult women, and 1 was 
an 8-year-old girl. The patients’ mean 
age was 30 years (range 8–54 years). 
Three patients were seropositive and 
4 were seronegative for HIV infection 
(the HIV status of 3 patients was un-
known). Data on prior anti-TB treat-
ment was available for 7 case-patients, 
of whom only 1 had a history of ante-
cedent TB chemotherapy. Altogether, 
3 patients died before completing 
treatment, including 2 patients affect-
ed by miliary TB, 1 of whom was HIV-
coinfected. The third patient who died 
was a student without a known history 
of immunosuppression or previous TB 
who had lived for 2 years in Spain. We 
could not establish any epidemiologic 
links between these patients during 
their stay in Spain.
Analysis of drug resistance genes 
showed that all isolates harbored the 
inhA promoter mutation –15C→T (6). 
Alterations in the inhA gene were pre-
viously reported in 80% of the isoni-
azid-resistant isolates from Equatorial 
Guinea (5). Notably, a double mutation 
in the rpoB gene affecting codons 531 
(Ser531Leu) and 561 (Ile561Val) was 
detected in the 10 MDR isolates. The 
presence of this uncommon mutation, 
Ile561Val, outside the rifampin resis-
tance–determining region supports the 
hypothesis that the MDR isolates are 
clonal in origin. Furthermore, we dem-
onstrated the absence of Ile561Val mu-
tation in 3 drug-susceptible M. tuber-
culosis strains with an SIT177-LAM 9 
spoligotype pattern, which ruled out a 
relationship between this spoligotype 
and the Ile561Val mutation.
Further analysis with phyloge-
netic markers assigned MDR-TBEG 
to the principal genetic group 2, the 
Euro-American lineage of M. tuber-
culosis and its West African sublin-
eage, on the basis of polymorphisms 
in codons katG463 and gyrA95, the 
7-bp pks15/1 deletion, and RD174 
(7,8), respectively. The analysis of 
the RDRio deletion conﬁ  rmed that the 
strain belongs to the major RDRio sub-
lineage of the LAM M. tuberculosis 
spoligotype family (9). This sublin-
eage is a major cause of TB in Rio 
de Janeiro (Brazil) but has dissemi-
nated globally. Additional informa-
tion on the geographic distribution of 
SIT177-LAM 9 was obtained from 
the updated International Spoligotyp-
ing Database (SITVIT2) of the Insti-
tut Pasteur de Guadeloupe. SITVIT2 
(consulted on 23 July 2008) contained 
57 isolates belonging to SIT177. Al-
most 50% (n = 28) came from Brazil, 
and 14% from Africa (Morocco, n = 
6; Senegal, n = 2). The remaining iso-
lates with known countries of origin 
(n = 9) were distributed in other un-
related countries. These data indicate 
that this particular spoligotype pat-
tern is widely distributed.
We identiﬁ  ed 1 MDR strain of M. 
tuberculosis RDRio sublineage isolated 
in Spain from Equatorial Guinean pa-
tients. Although the transmission of 
MDR-TBEG in Spain could not be 
conclusively ruled out, the fact that 
MDR TB developed in most patients 
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Figure. Genetic proﬁ  le of the multidrug-resistant tuberculosis Equatorial Guinea strain (MDR-
TBEG). RFLP, restriction fragment length polymorphism; SIT, spoligotype international type; 
LAM, Latin American-Mediterranean; MIRU-VNTR, mycobacterial interspersed repetitive-
unit variable-number tandem-repeat. MIRU-VNTR loci order: MIRU 02, VNTR 42, VNTR 
43, MIRU 04, MIRU 40, MIRU 10, MIRU 16, 1955, MIRU 20, QUB-11b, ETRA, VNTR 46, 
VNTR 47, VNTR 48, MIRU 23, MIRU 24, MIRU 26, MIRU 27, VNTR 49, MIRU 31, VNTR 
52, QUB-26, VNTR 53, MIRU 39.LETTERS
within 3 months after their arrival, as 
well as the spatiotemporal distribution 
of the MDR TB cases and its clonal 
origin, strongly suggest that MDR-
TBEG was imported into Spain and 
that active transmission of this partic-
ular clone could be occurring in Equa-
torial Guinea. However, additional 
molecular and epidemiologic studies 
should be conducted in this sub-Saha-
ran country to ascertain its role in re-
cent transmission of MDR TB. Greater 
international efforts should be made to 
provide appropriate tools to resource-
limited areas for ﬁ  ghting against MDR 
TB and preventing development of ex-
tensively drug-resistant TB. 
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